Pfizer on Monday won a bid in a London court to invalidate two of GSK's patents relating to a respiratory syncytial virus ...

Pfizer (PFE) has reportedly succeeded in getting a U.K. court to invalidate two of GSK’s (GSK) patents for its RSV vaccine.

Pfizer Inc. (NYSE:PFE) stock is trading higher with a session volume of 31.16 million as per data from Benzinga Pro. Activist ...

Low uptake in the RSV and COVID vaccine markets is not surprising, an analyst said, and could mean weak earnings for ...

As the Centers for Disease Control and Prevention (CDC) finds that only one-quarter of older adults have received their ...

Mary Kennedy and GSK Ireland launch Respiratory Syncytial Virus (RSV) awareness campaign encouraging over 65s and at-risk ...

GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that Arexvy has been approved in Malaysia for respiratory ...

The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.

First discovered in chimpanzees in 1956 and in children the following year, respiratory syncytial virus (RSV) isn’t new.

This study aimed to assess the short-term immune response of an RSV vaccine in a population of older adults 60 years and ...

A new study highlights risk factors for hospitalization and severe illness among adults with respiratory syncytial virus (RSV ...

Spread of the virus is seasonal, with activity often picking up in the fall after kids go back to school. Activity usually ...